Monitor for potential selling pressure as the December 12, 2026 lock-up expiration approaches. The stock's current price ($2.69) is 73% below the PIPE price ($10.00), suggesting PIPE investors are deeply underwater and may be motivated sellers once restrictions lift. The company's pre-clinical stage, declining revenue, and cash burn rate (~$1.9M operating cash used in 2025) suggest additional capital raises are likely, which could further pressure the stock.
Executive Summary
SL Science Holding Ltd filed an F-1 registration statement to register up to 1,040,000 ordinary shares for resale by PIPE investors who participated in the $7.8M PIPE financing that closed alongside the June 12, 2026 business combination with SPAC Horizon Space Acquisition II Corp. The company is a pre-revenue, pre-clinical-stage Taiwanese biomedical firm developing Armed-T and Gamma Delta T cell therapies for cancer, with no FDA approvals, no IND filed, and a legacy exosome cosmetics business that generated $2.2M in 2025 revenue (down 35% YoY). The filing is a routine resale registration that does not raise new capital for the company, but the lock-up expiration in December 2026 introduces potential overhang from the 1.04M shares being registered.
Key Financial Metrics
Key Facts
- F-1 registers up to 1,040,000 ordinary shares for resale by PIPE investors (780,000 shares held + 260,000 shares issuable upon preferred share conversion).
- Lock-up period expires December 12, 2026 (six months after the June 12, 2026 business combination closing).
- Company has no FDA-approved products, no IND filed, and all three product candidates (CD-19 Armed-T, GDT for pancreatic cancer, GDT for brain cancer) are in pre-clinical trials.
- 2025 revenue was $2.2M (down 35% YoY from $3.4M), with a net loss of $3.8M and accumulated deficit of $5.5M as of Dec 31, 2025.
- Top two corporate customers accounted for 95.3% of 2025 revenue; single-source supplier for exosome products.
- CEO William Wang controls 59.53% of voting power; company qualifies as a 'controlled company' under Nasdaq rules.
- Auditor (ARK Pro CPA & Co) is based in Hong Kong; PCAOB access risk noted under HFCAA.
- PIPE financing raised $7.8M gross proceeds at $10.00 per unit; stock closed at $2.69 on July 30, 2026.
Financial Impact
No new capital raised for the company. The PIPE financing raised $7.8M at $10.00/unit, but the stock trades at $2.69, implying the registered shares represent potential selling pressure of ~$2.8M at current prices.
Risk Factors
- Lock-up expiration in December 2026 creates overhang risk from 1.04M registered shares.
- Pre-revenue cell therapy pipeline with no FDA approvals, no IND filed, and uncertain clinical timelines.
- Revenue declined 35% YoY; net loss of $3.8M in 2025; accumulated deficit of $5.5M.
- Heavy customer concentration (95.3% from two customers) and single-source supplier risk.
- PCAOB/HFCAA delisting risk due to Hong Kong-based auditor.
- Taiwan/China geopolitical risk; Taiwan-specific regulatory and FX risks.
- Related-party conflicts: CEO owns 12.6% of CytoArm (key licensor); CTO owns 76% of JY BioMed (key licensor).
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 10 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| F-1 Filing (Primary) | 0001104659-26-089195 |
| Document: tmb-20260331xex5d1.htm | 0001104659-26-089195 |
| Document: tmb-20260331xexfees.htm | 0001104659-26-089195 |
| Document: tmb-20260331xex21d1.htm | 0001104659-26-089195 |
| Document: tmb-20260331xex23d3.htm | 0001104659-26-089195 |
| Document: tmb-20260331xex23d2.htm | 0001104659-26-089195 |
| Document: tmb-20260331xex23d4.htm | 0001104659-26-089195 |
| Document: 0001104659-26-089195-index-headers.html | 0001104659-26-089195 |
| Document: 0001104659-26-089195-index.html | 0001104659-26-089195 |
| Document: 0001104659-26-089195.txt | 0001104659-26-089195 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 1d ago | 6-K | $1.24 | awaiting T+20 | — | $1.23 (−0.81%) |
Oct 26, 2026 1d ago | Press Release | $1.24 | awaiting T+20 | — | $1.23 (−0.81%) |
Oct 1, 2026 26d ago | SC 13D/A | $1.57 | awaiting T+20 | — | $1.23 (−21.66%) |
Aug 13, 2026 10w ago | EFFECT | $2.71 $2.06 | ▼ −23.99% | ▼ −22.24% | $1.23 (−54.61%) |
Jul 31, 2026 12w ago | F-1 | $3.29 $2.73 | ▼ −17.02% | ▼ −18.26% | $1.23 (−62.61%) |
Jul 10, 2026 15w ago | 6-K | $4.73 $2.67 | ▼ −43.55% | ▼ −45.98% | $1.23 (−74.00%) |
Jun 18, 2026 18w ago | 20-F | $4.52 $4.30 | ▼ −4.87% | ▼ −4.72% | $1.23 (−72.79%) |
Jun 17, 2026 18w ago | 3 | $6.38 $4.33 | ▼ −32.13% | ▼ −33.45% | $1.23 (−80.72%) |
Jun 15, 2026 19w ago | 3 | $3.33 $4.33 | ▲ +30.03% | ▲ +30.78% | $1.23 (−63.06%) |
Jun 15, 2026 19w ago | 6-K | $3.33 $4.33 | ▲ +30.03% | ▲ +30.78% | $1.23 (−63.06%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers